PROCANBID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PROCANBID (PROCANBID).
Class Ia antiarrhythmic agent; inhibits sodium channels, slowing conduction velocity, increasing effective refractory period, and suppressing automaticity.
| Metabolism | Hepatic metabolism via N-acetyltransferase to N-acetylprocainamide (NAPA); also undergoes hydrolysis to p-aminobenzoic acid. |
| Excretion | Renal excretion: 50-60% unchanged; hepatic metabolism to N-acetylprocainamide (NAPA) with further renal elimination; total renal elimination of procainamide and NAPA >80%. |
| Half-life | Terminal elimination half-life: 2.5-4.7 hours (procainamide) with normal renal function; clinical context: prolonged in renal impairment (up to 14 hours) and heart failure; NAPA half-life: 6-8 hours. |
| Protein binding | 15-20% bound to serum proteins (primarily albumin). |
| Volume of Distribution | 1.5-2.5 L/kg; clinical meaning: extensive tissue distribution, with high uptake in heart, liver, and kidneys. |
| Bioavailability | Oral (immediate-release): 75-95%; oral (sustained-release): 75-90% relative to immediate release; IM: 100%. |
| Onset of Action | Oral: 30-60 minutes; IM: 10-30 minutes; IV: immediate (within minutes). |
| Duration of Action | Sustained-release (PROCANBID): 6-12 hours; clinical note: dosing interval based on procainamide and NAPA levels to maintain therapeutic concentration 4-10 mcg/mL. |
Procainamide extended-release (Procanbid) is dosed based on ideal body weight. Typical adult dose: 500 mg to 1500 mg orally every 12 hours. Maximum dose: 3000 mg/day. Dose should be titrated to achieve therapeutic plasma procainamide and NAPA levels.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | For CrCl 10-50 mL/min: administer every 12-24 hours; for CrCl <10 mL/min: administer every 24-48 hours. Reduce dose by 25-50% in renal impairment. Not recommended in severe renal failure. |
| Liver impairment | In Child-Pugh class A (mild): no adjustment necessary. Child-Pugh class B (moderate): reduce dose by 25-50%. Child-Pugh class C (severe): contraindicated due to accumulation and risk of toxicity. |
| Pediatric use | Not FDA approved for pediatric use. Dosing extrapolated from immediate-release formulations: 15-50 mg/kg/day orally in divided doses every 3-6 hours; maximum 4 g/day. Extended-release form not recommended in children. |
| Geriatric use | Initiate at lower end of dosing range (e.g., 500 mg every 12 hours) due to age-related renal decline. Monitor renal function and plasma levels closely; adjust dose according to CrCl. Increased risk of hypotension and proarrhythmia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PROCANBID (PROCANBID).
| Breastfeeding | Procainamide and its active metabolite N-acetylprocainamide (NAPA) are excreted in breast milk. The milk-to-plasma ratio is approximately 0.6 for procainamide and 1.9 for NAPA. Due to potential for adverse effects in nursing infants (e.g., hypotension, arrhythmias), avoid breastfeeding or use with caution, monitoring infant for signs of toxicity. |
| Teratogenic Risk | Procainamide, the active ingredient in PROCANBID, is pregnancy category C. Animal studies have shown teratogenic effects, but no adequate human studies exist. First trimester: potential risk of congenital anomalies based on animal data. Second and third trimesters: may cause maternal hypotension and reduced uterine blood flow, potentially leading to fetal hypoxia. Use only if benefit outweighs risk. |
■ FDA Black Box Warning
Procainamide can cause severe blood dyscrasias (e.g., agranulocytosis, neutropenia, thrombocytopenia) and should be reserved for life-threatening arrhythmias.
| Serious Effects |
Complete heart block (unless pacemaker in place); second-degree AV block; severe bradycardia; myasthenia gravis; hypersensitivity to procainamide or related drugs; history of drug-induced lupus.
| Precautions | May cause lupus-like syndrome (especially in slow acetylators); hypotension, QT prolongation, arrhythmogenic effects (torsades de pointes); caution in renal impairment (reduce dose), hepatic impairment, heart failure, and electrolyte disturbances. |
Loading safety data…
| Fetal Monitoring | Monitor maternal ECG, blood pressure, and heart rate during therapy. Assess for signs of procainamide toxicity (e.g., QRS widening, QT prolongation, hypotension). Fetal monitoring should include heart rate assessment; consider nonstress test or biophysical profile if prolonged therapy. Check maternal procainamide and NAPA serum levels periodically. |
| Fertility Effects | No known direct effects on human fertility. Animal studies have not reported impaired fertility. However, use in pregnancy should be avoided unless necessary. |